Search Results - Michel M van den Heuvel

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma

    External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma by Milou M. F. Schuurbiers, Freek A. van Delft, Hendrik Koffijberg, Maarten J. IJzerman, Kim Monkhorst, Marjolijn J. L. Ligtenberg, Daan van den Broek, Huub H. van Rossum, Michel M. van den Heuvel

    Published 2025-02-01

    Background Immune checkpoint inhibitors (ICIs) provide a significant survival benefit in non-small cell lung cancer (NSCLC) patients; however, accurately predicting which patients will benefit remains a challenge. As previously shown, the STOP model, a machine learning model based on serum tumor mar...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test

    A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test by Thomas Muley, Xiaotong Zhang, Stefan Holdenrieder, Catharina M Korse, Xiu-yi Zhi, Rafael Molina, Zhongjuan Liu, Gunther Hartmann, Michel M van den Heuvel, Kun Qian, Ramon Marrades, Christine Engel, Ying He, Birgit Wehnl, Farshid Dayyani, Felix Herth

    Published 2020-09-01

    This study aimed to investigate whether changes in progastrin-releasing peptide (ProGRP) levels correlate with treatment response and can be used to optimize clinical management of patients with small-cell lung cancer. Patients with small-cell lung cancer (any stage) receiving chemotherapy were elig...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial

    Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlle... by Wietske Kievit, C Jacobs, S Teerenstra, W Kievit, Steven Teerenstra, M de Vries, Iris Walraven, S R Rutgers, Colin Jacobs, J W G van Putten, Nicole E Billingy, Annemarie Becker-Commissaris, Idris Bahce, M Youssef, Cornelia A Verberkt, Suresh Senan, Marloes J Hassing, Joran Schoorlemmer, Merve Sarioglu, Erik H J G Aarntzen, Emile F I Comans, Astrid Keijser, Michel M van den Heuvel, N C van Walree, C J van Loenhout, Y Berk, R C Boshuizen, K J G Schulkes, M van Laren, M Schiefer, J Dits, E Lammers, E J Geraedts, K W Maas, P Brocken, A C M Mulders, S C van ‘t Westeinde, E Citgez, J N A van Diessen, E A Kastelijn, M A Kroeze, J M W van Haarst, A S R Lindert, I Bahce, S Senan, E F I Comans, N E Billingy, C A Verberkt, M Hassing, J Schoorlemmer, E H J G Aarntzen, M M van den Heuvel, I Walraven, A Becker-Commissaris

    Published 2025-07-01

    Introduction Patients with stage III non-small cell lung cancer (NSCLC) are at high risk of developing post-treatment recurrences (50–78%) during follow-up. As more effective treatments are now available, especially for patients with oligometastatic disease, earlier detection of recurrences may prol...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: